Loading
Loading
Research Overview
Combination of FSH and LH activity derived from post-menopausal urine; stimulates follicular development in women and spermatogenesis in men by activating gonadotropin receptors on gonadal tissue.
Overview
hMG is a preparation derived from the urine of postmenopausal women containing a mixture of FSH and LH activity. In preclinical reproductive biology research, it has been used to study the combined effects of FSH and LH receptor stimulation on follicular development, granulosa cell biology, and ovarian function in animal model systems. Its combined FSH/LH activity profile makes it useful for research models requiring coordinated gonadotropin stimulation.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Listed as prohibited under WADA anti-doping regulations
Prescription availability in Australia and internationally
In Australia, human menopausal gonadotropin (hmg) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Combination of FSH and LH activity derived from post-menopausal urine; stimulates follicular development in women and spermatogenesis in men by activating gonadotropin receptors on gonadal tissue.
Support
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.